Some studies indicated that EGFR tyrosine kinase (TK) inhibitor such as gefitinib, was useful for non-small cell lung cancer therapy in Japan in clinical trial phase II and III. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.